SEARCH

SEARCH BY CITATION

References

  • 1
    Säwe J., Kager L., Svensson JO, Rane A. Oral morphine in cancer patients; in vivo kinetics and in vitro hepatic glucuronidation. Br J clin Pharmac 1985; 19: 495501.
  • 2
    Hanna MH, Peat SJ, Woodham M., Knibb A., Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 1990; 64: 547550.
  • 3
    Bigler D., Christensen CB, Eriksen J., Jensen NH. Morphine, morphine-6 glucuronide and morphine-3-glucuronide concentrations in plasma and cerebrospinal fluid during long-term high-dose intrathecal morphine administration. Pain 1990; 41: 1518.
  • 4
    Osborne R., Joel S., Trew D., Slevin M. Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the active metabolite morphine-6-glucuronide. Clin Pharmac Ther 1990; 47: 1219.
  • 5
    Samuelsson H., Hedner T., Venn R., Michalkiewicz A. CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine. Pain 1993; 52: 179185.
  • 6
    Poulain P., Ribon M., Hanks G. CSF concentrations of morphine-6-glucuronide after oral administration of morphine. Pain 1990; 41: 115116.
  • 7
    Arnèr S., Arnèr B. Differential effects of epidural morphine in the treatment of cancer related pain. Acta Anesthesiol Scand 1985; 29: 3236.
  • 8
    Koopman-Kimenai PM, Vree TB, Cress-Tijhuis MW, Booij LH, Drijkoningen G. High-performance liquid chromatography and preliminary pharmacokinetics of nicomorphine and its metabolites 3-nicotinoyl- and 6-nicotinoylmorphine and morphine. J Chromatogr 1987; 416: 382387.
  • 9
    Khojasteh A., Evans W., Reynolds R., Thomas G., Savarese J. Controlled-release oral morphine sulphate in the treatment of cancer pain with pharmacokinetic correlation. J clin Oncol 1987; 5: 956961.
  • 10
    McQuay HJ, Carroll D., Faura C., Gavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: Influences on morphine and metabolite concentration. Clin Pharmac Ther 1990; 48: 236244.
  • 11
    Somogyi AA, Nation RL, Olweny Ch, et al. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. Clin Pharmacokin 1993; 24: 413420.
  • 12
    Carrupt P., Testa B., Bechalany A., Tayar N., Descas P., Perrisoud D. Morphine-6 glucuronide and morphine-3-glucuronide as molecular chameleons with unexpected lipophilicity. J med Chem 1991; 34: 12721275.
  • 13
    Milne RW, Nation RL, Somogyi AA, Bochner F., Griggs W. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J clin Pharmac 1992; 34: 5359.
  • 14
    Wahlström A., Winblad B., Bixo M., Rane A. Human brain metabolism of morphine and naloxone. Pain 1988; 35: 121127.
  • 15
    Hull CJ. Passage of drugs across membranes. In Pharmacokinetics for anaesthesia, ed Hull CJ, 1991; 3239. Oxford, Butterworth-Heinemann Ltd.